Skeptical judge sides with smaller analytics firm against giant PointClickCare over data blocking tactics

A federal judge sided with Real Time Medical Systems, which claimed that PointClickCare had implemented improper data blocking tactics with its use of unsolvable CAPTCHAs. Judge Paula Xinis ruled that this tactic violated the 21st Century Cures Act and PointClickCare’s actions aimed to shut down a substantial portion of Real Time’s business, ultimately eliminating competition through a potential takeover. PointClickCare argued that the CAPTCHAs are used to prevent bot activity and address other security concerns surrounding the records in their database. This case highlights the increasingly competitive side of electronic health records, the rising complications that can surround accessing patients’ records, and the security measures organizations have in place. 

With over 25 years of experience behind us, Greenlight prioritizes the patient and their data’s security. Our HITRUST CSF certification validates the highest level of information protection assurance. As the use of EHRs continues to expand, the industry will see bumps in the road but we remain committed to secure and successful health journeys. Patients should never doubt the privacy surrounding their information or worry about who has access to it, which is why Greenlight will continue to always make security a priority. 

Read the full article: Skeptical judge sides with smaller analytics firm against giant PointClickCare over data blocking tactics

Recent Articles

Everest ransomware group targets healthcare sector

Everest ransomware group targets healthcare sector

The Russian ransomware-as-a-service group, Everest, has recently turned its attention to the healthcare sector. The group has been linked to 20 healthcare-based cyberattacks that took place between April 2021 and July 2024. Those affected have to spend years not only...

Decentralized Clinical Trials: Bust or Breakthrough?

Decentralized Clinical Trials: Bust or Breakthrough?

While the life science industry began piloting decentralized clinical trials (DCTs) more than 15 years ago, the COVID 19 pandemic led to tremendous growth, primarily out of necessity.  As the world shut down, DCTs became the only viable option for conducting...